LLY
LLY
Indicative, may be delayed. Not trading-grade data.
Recently viewed
Only on this browser · up to 5Ticker detail
LLY
Cached quote, historical USD prices, and attributed headlines.
AI-generated
AI overview
Latest LLY headlines
- Eli Lilly stock surged as cheaper drugs unlocked a bigger market [1]. - The company rallied 11% in a week following Q3 sales growth of 39% [4]. - Eli Lilly soared 11% in a week after a $5.5 billion guidance raise [5].
Generated Nov 01, 2026 · 11:00 UTC
- Eli Lilly stock surges as cheaper drugs unlock a bigger market — Yahoo Finance
- After Eli Lilly’s Explosive Earnings Report, Is It Too Late to Buy the Stock? — Yahoo Finance
- Prediction: $100 per Month Invested in Eli Lilly (LLY) Stock Will Be Worth This Much by 2030 — Yahoo Finance
- Eli Lilly Rallies 11% in a Week as Q3 Sales Jump 39%, “Exceeding Our Prior Expectations” — Yahoo Finance
- Eli Lilly Soars 11% in a Week on a $5.5 Billion Guidance Raise: “Beating on the Up” — Yahoo Finance
Summary of the linked headlines, not full-article analysis. AI can make mistakes; verify the sources. Not investment advice.
Historical price
23 observations · USD · Source: Yahoo Finance · Sep 30, 2026 · 13:30 UTC to Oct 30, 2026 · 13:30 UTC · latest observation may be incomplete.
News about LLY
- Eli Lilly stock surges as cheaper drugs unlock a bigger market ↗
- After Eli Lilly’s Explosive Earnings Report, Is It Too Late to Buy the Stock? ↗
- Prediction: $100 per Month Invested in Eli Lilly (LLY) Stock Will Be Worth This Much by 2030 ↗
- Eli Lilly Rallies 11% in a Week as Q3 Sales Jump 39%, “Exceeding Our Prior Expectations” ↗
- Eli Lilly Soars 11% in a Week on a $5.5 Billion Guidance Raise: “Beating on the Up” ↗
- Cathie Wood Loads Up On TEM, ILMN And Biotech Stocks — But Pares Stake In This Pharma Giant That Had A Blowout Q3 ↗
- What Eli Lilly and Company (LLY) Said on Its Q3 Earnings Call ↗
- Novo Nordisk (NYSE:NVO) Could Be 61% Undervalued Following Rising GLP 1 Competition ↗
- OmniAb, Inc. Q3 2026 Earnings Call Summary ↗
- LLY, ABBV Stocks Hit All-Time High – Here’s What’s Driving Investor Enthusiasm Today ↗
- Eli Lilly Is Now Worth as Much as Warren Buffett's Berkshire Hathaway. Can the Rally Keep Going? ↗
- Amazon earnings fall short amid tech sell-off, and Anthropic becomes SpaceX's top partner ↗
- Eli Lilly’s Next Trillion-Dollar Opportunity May Go Beyond Weight-Loss Drugs ↗
- Stock Market: Google, Amazon, Intel, ServiceNow Trigger Tech Wreck, But Other Sectors Solid: Weekly Review ↗
- Walmart & Eli Lilly join the pushback against blockchain-based stock trading ↗
- Eli Lilly raises earnings outlook as obesity drug demand drives strong growth, UBS says ↗
- Binance hacked, and withdrawals are now on hold, plus Nasdaq wants tokenization on its own terms ↗
- Fidelity’s Health Care ETF Holds the Biotechs XLV Skips. Retirees Should Know the Difference ↗
- Prediction markets herald insider trading risks for private biotechs ↗
- OmniAb Q3 Earnings Call Highlights ↗
Comments and bookmarks
Comments are plain text from NPDev accounts. Bookmarks stay private to the account that saved them.
No comments yet. Be the first to say something.
Sign in to join the conversation.